Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...

Researchers discovered inconsistent use of immune checkpoint inhibitors (ICIs) after disease progression in patients who were ...

In an interview with Targeted Oncology, Jaime Merchan, MD, delved into data from the LITESPARK-013 trial evaluating ...

These cystic tumors are extremely difficult to distinguish based on clinical, radiological, and gross features, and they can cause a diagnostic dilemma. Cystic renal cell carcinoma is a ...

Neoadjuvant therapy for high-risk renal cell carcinoma (RCC) may offer a survival advantage over adjuvant therapy, according to data presented at the 2024 annual meeting of the Society of Urologic ...

(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, ...

Patients with metastatic renal cell carcinoma staged pT1-4 Nx M1 were ... or second malignancy or participants in other clinical trials were excluded from this study. Patient recruitment started ...

Jaime Merchan, MD, discusses the efficacy results observed in the LITESPARK-013 trial of belzutifan in patients with advanced clear cell renal cell carcinoma.

Sorafenib is US FDA approved for the treatment of advanced renal cell carcinoma ... one of these agents. The Trials to Investigate the Effects of Sorafenib in Breast Cancer program The Trials ...

The CHMP's opinion is based on positive results from two late-stage studies on MRK's Welireg in two indications associated ...

Australian biotechnology company, Telix Pharmaceuticals, has announced that it has dosed the first patient as part of its Phase III ZIRCON-CP trial of TLX250-CDx, a form of positron emission ...